MX2016017388A - Metodos para tratar o aliviar la migraña. - Google Patents
Metodos para tratar o aliviar la migraña.Info
- Publication number
- MX2016017388A MX2016017388A MX2016017388A MX2016017388A MX2016017388A MX 2016017388 A MX2016017388 A MX 2016017388A MX 2016017388 A MX2016017388 A MX 2016017388A MX 2016017388 A MX2016017388 A MX 2016017388A MX 2016017388 A MX2016017388 A MX 2016017388A
- Authority
- MX
- Mexico
- Prior art keywords
- migraine
- methods
- treating
- administering
- partial agonist
- Prior art date
Links
- 206010027599 migraine Diseases 0.000 title abstract 7
- 208000019695 Migraine disease Diseases 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 5
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 abstract 3
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract 3
- 239000004031 partial agonist Substances 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 230000001054 cortical effect Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010049714 Abdominal migraine Diseases 0.000 abstract 1
- 208000006561 Cluster Headache Diseases 0.000 abstract 1
- 208000005056 Ophthalmoplegic Migraine Diseases 0.000 abstract 1
- 206010052784 Retinal migraine Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 208000018912 cluster headache syndrome Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000001667 episodic effect Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 230000000737 periodic effect Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En ciertas modalidades, la invención se refiere a métodos para tratar la migraña (por ejemplo, migraña episódica, migraña crónica, migraña retiniana, migraña oftalmopléjica, migraña acefálica, trastorno migrañoso, migraña menstrual, migraña abdominal, síndromes periódicos infantiles o cefalea en racimos) al administrar un péptido con agonista parcial de NMDAR. En ciertas modalidades, la invención también se refiere a métodos para tratar o aliviar las secuelas posteriores a la migraña a largo plazo en un paciente al administrar un péptido con agonista parcial de NMDAR. En otras ciertas modalidades, la invención se refiere a métodos para tratar, suprimir o prevenir la depresión de extensión cortical o una enfermedad o padecimiento causado por depresión de extensión cortical en un paciente en necesidad del mismo, que comprende administrar un péptido con agonista parcial de NMDAR. Por ejemplo, en la presente se proporcionan métodos para tratar epilepsia, lesión cerebral traumática y/o derrame cerebral.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462015727P | 2014-06-23 | 2014-06-23 | |
| US201562109386P | 2015-01-29 | 2015-01-29 | |
| PCT/US2015/037177 WO2015200322A1 (en) | 2014-06-23 | 2015-06-23 | Methods of treating or ameliorating migraine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016017388A true MX2016017388A (es) | 2018-02-19 |
Family
ID=54938737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016017388A MX2016017388A (es) | 2014-06-23 | 2015-06-23 | Metodos para tratar o aliviar la migraña. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3157943A4 (es) |
| JP (2) | JP6688748B2 (es) |
| KR (1) | KR20170018072A (es) |
| CN (1) | CN106661085A (es) |
| AU (1) | AU2015280108B2 (es) |
| BR (1) | BR112016030375A8 (es) |
| CA (1) | CA2953170A1 (es) |
| MX (1) | MX2016017388A (es) |
| RU (1) | RU2721401C2 (es) |
| WO (1) | WO2015200322A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7476229B2 (ja) * | 2019-04-15 | 2024-04-30 | フェリン・ファーマシューティカルズ・インコーポレイテッド | 片頭痛の治療 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995006468A1 (en) * | 1993-09-01 | 1995-03-09 | Smithkline Beecham Corporation | Method for treating migraine headaches |
| DE60127459T2 (de) * | 2000-08-25 | 2007-07-12 | Research Corp. Technologies, Inc., Tucson | Verwendung von aminosäurehaltigen Antikonvulsiva zur Behandlung von Schmerz |
| AU2002227929A1 (en) * | 2000-11-17 | 2002-05-27 | Bayer Aktiengesellschaft | Regulation of human nmda receptor |
| BRPI0408131A (pt) * | 2003-03-06 | 2006-03-01 | Botulinum Toxin Res Ass Inc | tratamento com toxina botulina de dor facial e cefaléia crÈnicas relacionadas com sinusite |
| BRPI0916203A2 (pt) * | 2008-07-23 | 2018-05-15 | Kyowa Hakko Kirin Co Ltd | agente terapêutico e/ou preventivo para enxaqueca, método para tratar e/ou prevenir enxaqueca, e, uso de um composto |
| US20120178695A1 (en) * | 2009-07-02 | 2012-07-12 | Joseph Moskal | Methods of treating neuropathic pain |
| WO2011044089A2 (en) * | 2009-10-05 | 2011-04-14 | Joseph Moskal | Methods of treating depression and other related diseases |
| US8951968B2 (en) * | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| ES2706063T3 (es) * | 2010-02-11 | 2019-03-27 | Univ Northwestern | Agonistas del receptor de NMDA y usos del mismo |
| KR20180095096A (ko) * | 2011-04-27 | 2018-08-24 | 노오쓰웨스턴 유니버시티 | 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법 |
| CA2887875A1 (en) * | 2012-10-12 | 2014-04-17 | Northwestern University | Methods of identifying compounds for treating depression and other related diseases |
-
2015
- 2015-06-23 KR KR1020177001848A patent/KR20170018072A/ko not_active Ceased
- 2015-06-23 MX MX2016017388A patent/MX2016017388A/es unknown
- 2015-06-23 BR BR112016030375A patent/BR112016030375A8/pt not_active IP Right Cessation
- 2015-06-23 EP EP15811633.5A patent/EP3157943A4/en not_active Withdrawn
- 2015-06-23 CN CN201580033913.6A patent/CN106661085A/zh active Pending
- 2015-06-23 AU AU2015280108A patent/AU2015280108B2/en not_active Ceased
- 2015-06-23 CA CA2953170A patent/CA2953170A1/en not_active Abandoned
- 2015-06-23 RU RU2017101410A patent/RU2721401C2/ru active
- 2015-06-23 WO PCT/US2015/037177 patent/WO2015200322A1/en not_active Ceased
- 2015-06-23 JP JP2016575106A patent/JP6688748B2/ja active Active
-
2020
- 2020-04-06 JP JP2020068289A patent/JP2020114863A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017101410A3 (es) | 2019-01-21 |
| AU2015280108A1 (en) | 2017-01-19 |
| JP2020114863A (ja) | 2020-07-30 |
| JP2017519778A (ja) | 2017-07-20 |
| BR112016030375A8 (pt) | 2021-07-13 |
| EP3157943A1 (en) | 2017-04-26 |
| JP6688748B2 (ja) | 2020-04-28 |
| RU2017101410A (ru) | 2018-07-24 |
| AU2015280108B2 (en) | 2019-11-28 |
| WO2015200322A1 (en) | 2015-12-30 |
| BR112016030375A2 (pt) | 2017-08-15 |
| EP3157943A4 (en) | 2018-01-24 |
| CN106661085A (zh) | 2017-05-10 |
| RU2721401C2 (ru) | 2020-05-19 |
| KR20170018072A (ko) | 2017-02-15 |
| CA2953170A1 (en) | 2015-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016010854A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de un antagonista de il-4r. | |
| MX394909B (es) | Uso de la akkermansia pasteurizada para tratar trastornos metabolicos | |
| MY199027A (en) | Method for treating or preventing ophthalmological conditions | |
| PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| DOP2017000268A (es) | Metodos y kits para tratar depresion | |
| MX2018003388A (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| PH12016501966B1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| MX2015015249A (es) | Peptidos terapeuticos. | |
| GB2541571A (en) | Pharmaceutical compositions | |
| MX390084B (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| EP4137147A3 (en) | Uses of abaloparatide in reducing fracture risk | |
| EA201691020A1 (ru) | Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина" | |
| MX2016008108A (es) | Angiotensina ii sola o en combinacion para el tratamiento de hipotension. | |
| EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
| MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
| CO2020005485A2 (es) | Administración oral de análogos del péptido glp-1 | |
| MX2015010296A (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. | |
| MX391926B (es) | Uso de medicamentos con propiedades neuroprotectoras para prevenir o reducir el riesgo del daño por isquemia-reperfusion en un sujeto. | |
| WO2016134257A8 (en) | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders | |
| MX2020005952A (es) | Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos. | |
| MX381429B (es) | Tricostatina a (tsa) para usarse en el tratamiento del cáncer. | |
| MX2019014090A (es) | Métodos para el tratamiento de la reservoritis crónica. | |
| MX386151B (es) | Uso de tricostatina a (tsa) en el tratamiento del mieloma múltiple. | |
| MX2016017388A (es) | Metodos para tratar o aliviar la migraña. | |
| MX374938B (es) | Un método para el tratamiento de trastornos del movimiento con befiradol. |